CRISPR/Cas9 technology to inactivate cancer mutations

(Technische Universität Dresden) As for many other biomedical and biotechnology disciplines, the genome scissor 'CRISPR/Cas9' also opens up completely new possibilities for cancer research. Scientists of the National Center for Tumor Disease, the German Consortium for Translational Cancer Research and the Medical Faculty of the TU Dresden have shown that mutations that act as cancer drivers can be targeted and repaired. The most relevant mutations could therefore be diagnosed faster, improving personalized therapies.